Congress reprises FDA heparin probe; Big pharma lobbies for tougher theft penalties;

> House Republican Fred Upton wants the FDA's documentation from its probe of the 2008 incident of contaminated heparin from China: "There is reason to believe all or some of the individuals responsible for the adulteration are still actively engaged in the Chinese pharmaceutical supply chain." Story

> Abbott Labs, GlaxoSmithKline, J&J and Novo Nordisk have formed a coalition to push for tougher penalties for drug theft. Article

> Purdue Pharma's RxPATROL collaboration has donated $2,500 to the group Silent Witness, increasing the reward for information on a Phoenix heist of 6,200 OxyContin pills. Story

> The Royal Pharmaceutical Society finds Scotland's supply chain "brittle." Story

> Swiss API maker Carbogen Amcis is eliminating 60 of its 350 positions due to restructuring. Carbogen Amcis release

> Pristine Pharma Corp has begun operations at its new Massena, NY-based manufacturing plant  following FDA registration. Pristine release

> The Armenian pharmaceutical industry will apply GMP standards by 2013 to increase drug exports. Story

> Contract manufacturer ScinoPharm has contracted with Clinical Data and will produce vilazodone hydrochloride, the API for the latter's newly approved depression treatment, Viibryd. Story

Suggested Articles

The FDA has found issues with the testing practices of a U.S. generics maker that had specific problems with ADHD and weight-loss drugs.

A warning letter says Chinese API maker Yibin Lihao Bio-technical was found lying to the FDA about manufacturing unapproved heparin.

It took four tries over four years, but Perrigo has finally gotten FDA approval of its generic of Teva’s tricky-to-make ProAir HFA asthma inhaler.